Payment overview · 2025
General Payments
$1,335.05
81 reported records · 11 companies
Healthcare provider profile · identity verified
Ferdinand Tabucol Roda, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · HOT SPRINGS, AR · NPI 1124127634
Verified facts
What the public records show
CMS Open Payments records show Ferdinand Tabucol Roda, M.D. received $1,335.05 in general payments during 2025 across 81 reported records.
E.R. Squibb & Sons, L.L.C. accounted for 17.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Ingrezza, Rexulti, Zenpep.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Zenpep by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 495 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 171 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Rexulti by this doctor in 2024.
Neurocrine BioSciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported INGREZZA as an associated drug or biological on 126456 records involving 27390 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ingrezza by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 103 claims for Rexulti by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 549 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $230.21 | 17.2% | 8 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $226.44 | 17.0% | 8 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $216.52 | 16.2% | 13 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $196.10 | 14.7% | 19 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $174.02 | 13.0% | 10 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $147.69 | 11.1% | 15 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $42.65 | 3.2% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $41.87 | 3.1% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.83 | 1.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.94 | 1.5% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.78 | 1.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,207.79 | 79 |
| Education | $127.26 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $390.54 | 23 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $230.21 | 8 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $196.10 | 19 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $147.69 | 15 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $126.45 | 7 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $114.96 | 11 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $42.65 | 3 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $41.87 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $23.83 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $15.78 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 549 | exact normalized | Medicare Part D |
| INGREZZA ingrezza |
2025 | Ingrezza | 2024 | 63 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 103 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
495 | 77 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
171 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
103 | 19 |
| Neurocrine BioSciences, Inc. Exact reporting entity; no affiliate inference |
2025 | INGREZZA open payments reported associated product |
CMS Open Payments — General Payments 126456 supporting records · 27390 recipient NPIs · example record 1242766729 |
Ingrezza · 2024 Exact normalized brand match · 1 Part D row |
63 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
103 | 19 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
549 | 52 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 726 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 642 | 129 |
| Gabapentin | Gabapentin | 566 | 115 |
| Gemtesa | Vibegron | 549 | 52 |
| Lisinopril | Lisinopril | 547 | 107 |
| Pantoprazole Sodium | Pantoprazole Sodium | 507 | 115 |
| Amlodipine Besylate | Amlodipine Besylate | 497 | 103 |
| Eliquis | Apixaban | 495 | 77 |
| Potassium Chloride | Potassium Chloride | 446 | 117 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 439 | 101 |
| Furosemide | Furosemide | 412 | 107 |
| Memantine Hcl | Memantine Hcl | 387 | 74 |
| Metformin Hcl | Metformin Hcl | 337 | 60 |
| Sertraline Hcl | Sertraline Hcl | 335 | 71 |
| Clopidogrel | Clopidogrel Bisulfate | 328 | 72 |
| Metoprolol Tartrate | Metoprolol Tartrate | 313 | 70 |
| Montelukast Sodium | Montelukast Sodium | 301 | 52 |
| Trazodone Hcl | Trazodone Hcl | 267 | 67 |
| Donepezil Hcl | Donepezil Hcl | 262 | 50 |
| Divalproex Sodium | Divalproex Sodium | 252 | 43 |
| Tramadol Hcl | Tramadol Hcl | 240 | 56 |
| Carvedilol | Carvedilol | 230 | 51 |
| Pravastatin Sodium | Pravastatin Sodium | 224 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 48 |
| Lorazepam | Lorazepam | 203 | 48 |
| Entresto | Sacubitril/Valsartan | 200 | 19 |
| Allopurinol | Allopurinol | 193 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 185 | 44 |
| Omeprazole | Omeprazole | 181 | 49 |
| Clonazepam | Clonazepam | 177 | 33 |
| Jardiance | Empagliflozin | 171 | 24 |
| Meloxicam | Meloxicam | 171 | 36 |
| Levetiracetam | Levetiracetam | 168 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 41 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 166 | 41 |
| Mirtazapine | Mirtazapine | 159 | 43 |
| Buspirone Hcl | Buspirone Hcl | 158 | 36 |
| Losartan Potassium | Losartan Potassium | 157 | 42 |
| Famotidine | Famotidine | 152 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 37 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 146 | 18 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 36 |
| Quetiapine Fumarate | Quetiapine Fumarate | 134 | 33 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 39 |
| Simvastatin | Simvastatin | 128 | 21 |
| Alendronate Sodium | Alendronate Sodium | 127 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 121 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 33 |
| Spironolactone | Spironolactone | 114 | 29 |
| Linzess | Linaclotide | 113 | 33 |
| Zolpidem Tartrate | Zolpidem Tartrate | 113 | 19 |
| Diltiazem Hcl | Diltiazem Hcl | 107 | 17 |
| Xarelto | Rivaroxaban | 107 | 13 |
| Rexulti | Brexpiprazole | 103 | 19 |
| Hydralazine Hcl | Hydralazine Hcl | 100 | 23 |
| Ondansetron Hcl | Ondansetron Hcl | 99 | 43 |
| Ropinirole Hcl | Ropinirole Hcl | 98 | 20 |
| Venlafaxine Hcl | Venlafaxine Hcl | 97 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 94 | 42 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 93 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 40 |
| Farxiga | Dapagliflozin Propanediol | 90 | 16 |
| Bumetanide | Bumetanide | 89 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 20 |
| Sucralfate | Sucralfate | 87 | 16 |
| Prednisone | Prednisone | 86 | 48 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 85 | 17 |
| Hydrochlorothiazide | Hydrochlorothiazide | 79 | 19 |
| Glipizide | Glipizide | 77 | 16 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 73 | 13 |
| Baclofen | Baclofen | 71 | 17 |
| Alprazolam | Alprazolam | 70 | suppressed |
| Finasteride | Finasteride | 70 | 17 |
| Movantik | Naloxegol Oxalate | 70 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 53 |
| Benztropine Mesylate | Benztropine Mesylate | 65 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 65 | 44 |
| Vascepa | Icosapent Ethyl | 64 | suppressed |
| Ingrezza | Valbenazine Tosylate | 63 | suppressed |
| Latanoprost | Latanoprost | 63 | 15 |
| Propafenone Hcl | Propafenone Hcl | 63 | suppressed |
| Sotalol | Sotalol Hcl | 63 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 63 | 17 |
| Azithromycin | Azithromycin | 62 | 47 |
| Fluoxetine Hcl | Fluoxetine Hcl | 62 | 17 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 62 | 14 |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 61 | 11 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 60 | 14 |
| Ventolin Hfa | Albuterol Sulfate | 56 | 18 |
| Fluconazole | Fluconazole | 54 | 34 |
| Olanzapine | Olanzapine | 54 | 13 |
| Lidocaine Hcl | Lidocaine Hcl | 53 | 38 |
| Cefdinir | Cefdinir | 52 | 38 |
| Ondansetron Odt | Ondansetron | 52 | 15 |
| Pregabalin | Pregabalin | 52 | 12 |
| Admelog | Insulin Lispro | 51 | 14 |
| Aripiprazole | Aripiprazole | 50 | 11 |
| Clonidine Hcl | Clonidine Hcl | 49 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 49 | 21 |
| Divalproex Sodium Er | Divalproex Sodium | 49 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 49 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 48 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 48 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 48 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 48 | 25 |
| Novolog | Insulin Aspart | 46 | 11 |
| Roflumilast | Roflumilast | 46 | suppressed |
| Risperidone | Risperidone | 44 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 43 | suppressed |
| Ozempic | Semaglutide | 43 | suppressed |
| Clozapine | Clozapine | 42 | suppressed |
| Levofloxacin | Levofloxacin | 42 | 33 |
| Myrbetriq | Mirabegron | 42 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 41 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 39 | 21 |
| Promethazine Hcl | Promethazine Hcl | 39 | 16 |
| Amantadine | Amantadine Hcl | 38 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 38 | suppressed |
| Ezetimibe | Ezetimibe | 38 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 38 | 19 |
| Metformin Hcl Er | Metformin Hcl | 38 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 36 | 11 |
| Diazepam | Diazepam | 36 | suppressed |
| Lacosamide | Lacosamide | 36 | suppressed |
| Lactulose | Lactulose | 36 | 13 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 36 | 12 |
| Bupropion Xl | Bupropion Hcl | 35 | 15 |
| Mounjaro | Tirzepatide | 35 | suppressed |
| Cephalexin | Cephalexin | 34 | 24 |
| Novolin R | Insulin Regular, Human | 34 | suppressed |
| Nystatin | Nystatin | 34 | 24 |
| Megestrol Acetate | Megestrol Acetate | 33 | 11 |
| Ranolazine Er | Ranolazine | 33 | suppressed |
| Glimepiride | Glimepiride | 31 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 31 | 19 |
| Nifedipine Er | Nifedipine | 30 | suppressed |
| Nystop | Nystatin | 30 | 21 |
| Sodium Chloride | 0.9 % Sodium Chloride | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | 14 |
| Trulicity | Dulaglutide | 29 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 27 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 27 | suppressed |
| Methocarbamol | Methocarbamol | 27 | 12 |
| Zenpep | Lipase/Protease/Amylase | 27 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 26 | 14 |
| Morphine Sulfate | Morphine Sulfate | 26 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 26 | suppressed |
| Renvela | Sevelamer Carbonate | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | suppressed |
| Fentanyl | Fentanyl | 25 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 25 | suppressed |
| Humalog | Insulin Lispro | 25 | suppressed |
| Valsartan | Valsartan | 25 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Atenolol | Atenolol | 24 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 24 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | suppressed |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Gemfibrozil | Gemfibrozil | 24 | suppressed |
| Januvia | Sitagliptin Phosphate | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | 12 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 24 | suppressed |
| Nitroglycerin | Nitroglycerin | 24 | 20 |
| Amoxicillin | Amoxicillin | 23 | 17 |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Digoxin | Digoxin | 23 | suppressed |
| Ertapenem | Ertapenem Sodium | 23 | 11 |
| Eszopiclone | Eszopiclone | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 12 |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Acyclovir | Acyclovir | 22 | suppressed |
| Corlanor | Ivabradine Hcl | 22 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Insulin Lispro | Insulin Lispro | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 21 | suppressed |
| Mupirocin | Mupirocin | 20 | 18 |
| Rayaldee | Calcifediol | 20 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 19 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Entacapone | Entacapone | 19 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 18 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 17 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 17 | suppressed |
| Rivastigmine | Rivastigmine | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 16 | 16 |
| Carbamazepine Er | Carbamazepine | 16 | suppressed |
| Dulera | Mometasone/Formoterol | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Estradiol | Estradiol | 16 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 16 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 16 | 12 |
| Levemir | Insulin Detemir | 16 | suppressed |
| Lithium Carbonate | Lithium Carbonate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Scopolamine | Scopolamine | 16 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Calcitriol | Calcitriol | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Primidone | Primidone | 15 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 14 | 13 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 14 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 14 | suppressed |
| Vancomycin Hcl | Vancomycin/Water For Inj (Peg) | 14 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 13 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 12 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 12 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Metronidazole | Metronidazole | 12 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 12 | suppressed |
| Anastrozole | Anastrozole | 11 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 11 | suppressed |
| Lumigan | Bimatoprost | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Pentoxifylline | Pentoxifylline | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,335.05 · 81 records | E.R. Squibb & Sons, L.L.C. | AUSTEDO XR, COBENFY, FANAPT, GEMTESA, HETLIOZ, INGREZZA, NUPLAZID, REXULTI, WATCHMAN Access System, ZENPEP, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Aimmune Therapeutics, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error